Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
The new capital is expected to fund the company through 2029
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
Comprehensive clinical development programs being initiated for each investigational candidate
New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.
Collaboration supports multiple discovery efforts, including vaccines
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Subscribe To Our Newsletter & Stay Updated
